Jie Bai

Jie Bai

Auto-generated profile, based on publicly available information

Jie Bai

Department of Occupational and Environmental Health School of Public Health Dalian Medical University Dalian P. R. China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
JBJie Bai
Jie Bai
LYLiangqingqing Yin
Liangqingqing Yin
WYWei-Jia Yu
Wei-Jia Yu
YZYUNLONG ZHANG
YUNLONG ZHANG
QLQiuyue Lin
Qiuyue Lin
HLHuihua Li
Huihua Li
Cardiac lymphatic vessel growth (lymphangiogenesis) and integrity play an essential role in maintaining tissue fluid balance. Inhibition of lymphatic lymphangiogenesis is involved in cardiac edema and cardiac remodeling after ischemic injury or pressure overload. However, whether lymphatic vessel integrity is disrupted during angiotensin II‐ (Ang II‐) induced cardiac remodeling remains to be investigated. In this study, cardiac remodeling models were established by Ang II (1000 ng/kg/min) in VEGFR‐3 knockdown (Lyve‐1Cre VEGFR‐3f/−) and wild‐type (VEGFR‐3f/f) littermates. Our results indicated that Ang II infusion not only induced cardiac lymphangiogenesis and upregulation of VEGF‐C and VEGFR‐3 expression in the time‐dependent manner but also enhanced proteasome activity, MKP5 and VE‐cadherin degradation, p38 MAPK activation, and lymphatic vessel hyperpermeability. Moreover, VEGFR‐3 knockdown significantly inhibited cardiac lymphangiogenesis in mice, resulting in exacerbation of tissue edema, hypertrophy, fibrosis superoxide production, inflammation, and heart failure (HF). Conversely, administration of epoxomicin (a selective proteasome inhibitor) markedly mitigated Ang II‐induced cardiac edema, remodeling, and dysfunction; upregulated MKP5 and VE‐cadherin expression; inactivated p38 MAPK; and reduced lymphatic vessel hyperpermeability in WT mice, indicating that inhibition of proteasome activity is required to maintain lymphatic endothelial cell (LEC) integrity. Our results show that both cardiac lymphangiogenesis and lymphatic barrier hyperpermeability are implicated in Ang II‐induced adaptive hypertrophic remodeling and dysfunction. Proteasome‐mediated hyperpermeability of LEC junctions plays a predominant role in the development of cardiac remodeling. Selective stimulation of lymphangiogenesis or inhibition of proteasome activity may be a potential therapeutic option for treating hypertension‐induced cardiac remodeling.

1 March 2014 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
PXPan Xu
Pan Xu
SDShouying Du
Shouying Du
YLYang Lu
Yang Lu
JBJie Bai
Jie Bai
YGYi-Wang Guo
Yi-Wang Guo
YCYan-Feng Cao
Yan-Feng Cao

5 April 2025 in EP Europace
Verified
Journal Article
Open access
HLHan Li
Han Li
ZFZhenyu Feng
Zhenyu Feng
BLBenke Li
Benke Li
JBJie Bai
Jie Bai
QLQiuyue Lin
Qiuyue Lin
XYXiaolei Yang
Xiaolei Yang
Aims: Atrial fibrillation is the most common arrhythmia in clinical practice and increases the potential risk of stroke, thromboembolism, and death. Glutathione-S-transferases pi 1 (GSTP1), a key factor of ferroptosis, can participate in stress signal and cell damage pathway through its non-catalytic activity, and has the role of regulating and protecting cells from carcinogens and electrophilic compounds. However, the role and mechanism of GSTP1 in angiotensin II-induced atrial fibrillation have not been studied. Methods and results: We constructed a mouse model of atrial fibrillation using Ang II and identified key factors by proteome and ferroptosis PCR array. We investigated the role of GSTP1 in atrial remodelling and NRAMs by the ferroptosis inhibitor Ferrostatin-1 (Fer-1), AAV9-cTNT-GSTP1, and GSTP1 inhibitor Ezatiostat. The results showed that the ferroptosis pathway was significantly altered in atrial fibrillation by proteomics. The ferroptosis inhibitor Fer-1 demonstrated that inhibiting ferroptosis can intervene in Ang II-induced atrial fibrillation. The ferroptosis PCR array showed that the expression of GSTP1 was significantly decreased in atrial fibrillation, and it was verified in cells and human atrial tissues. In mice infected with AAV9-cTNT-GSTP1, it was found that overexpression of GSTP1 inhibited Ang II-induced atrial fibrillation. Overexpression of GSTP1 inhibited Ang II-induced myocardial injury, oxidative stress, and ferroptosis in vitro. Conclusion: Therefore, these results preliminarily demonstrate that GSTP1-mediated ferroptosis plays a crucial role in the Ang II-induced atrial fibrillation model and can be considered a potential therapeutic target for atrial fibrillation.

26 October 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
ZFZhenyu Feng
Zhenyu Feng
YYYijin Yang
Yijin Yang
JBJie Bai
Jie Bai
PSPengqi Sun
Pengqi Sun
XSXuyang Sun
Xuyang Sun
YXYunpeng Xie
Yunpeng Xie
Doxorubicin (DOX) remains a widely used chemotherapeutic drug, yet its clinical value is constrained by pronounced cardiotoxicity. Although melatonin is known to protect the heart, how it counters DOX‐induced cardiotoxicity (DIC), and whether it interferes with chemotherapy, remains unclear. Here we set out to define how melatonin protects the heart during DOX treatment and to test whether this protection holds in tumor‐bearing animals. We used acute and chronic DIC mouse models together with a syngeneic melanoma‐bearing model, and combined transcriptomic profiling, pharmacological intervention, cardiomyocyte‐specific USP18 overexpression and knockout, co‐immunoprecipitation, mass spectrometry, ubiquitination assays, and PKM2 inhibitor treatment. Melatonin markedly improved cardiac function, an effect exerted mainly via the MT1/2 receptors. Mechanistically, DOX activated STAT1, which in turn drove myocardial USP18 upregulation. USP18 bound PKM2 and stabilized it through removing K33‐linked ubiquitin chains while favoring K27‐linked ubiquitination—thereby aggravating cardiac injury. Overexpressing USP18 specifically in cardiomyocytes worsened DIC and abolished the protection conferred by melatonin, whereas deleting USP18 or inhibiting PKM2 reproduced melatonin's benefits. Notably, in bearing melanoma or lymphoma, melatonin relieved DIC without weakening the antitumor activity of DOX. Together, these findings define a previously unrecognized cardioprotective pathway and provide preclinical support for melatonin as a safe adjunct therapy in cardio‐oncology.

1 January 2026 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
XXXiaofeng Xu
Xiaofeng Xu
TWTong Wang
Tong Wang
HLHaomiao Li
Haomiao Li
XLXinyue Liu
Xinyue Liu
JBJie Bai
Jie Bai
WQWei-Kun Qu
Wei-Kun Qu